Pharmala Biotech Holdings (XCNQ:MDMA) COGS-to-Revenue : 0.07 (As of Feb. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings COGS-to-Revenue?

Pharmala Biotech Holdings's Cost of Goods Sold for the three months ended in Feb. 2025 was C$0.01 Mil. Its Revenue for the three months ended in Feb. 2025 was C$0.15 Mil.

Pharmala Biotech Holdings's COGS to Revenue for the three months ended in Feb. 2025 was 0.07.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Pharmala Biotech Holdings's Gross Margin % for the three months ended in Feb. 2025 was 93.15%.

Pharmala Biotech Holdings COGS-to-Revenue Historical Data

The historical data trend for Pharmala Biotech Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings COGS-to-Revenue Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

COGS-to-Revenue

0.03

0.15

0.14

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24	Nov24	Feb25
COGS-to-Revenue	Get a 7-Day Free Trial										0.39	-	-	-	0.07

Pharmala Biotech Holdings COGS-to-Revenue Calculation

Pharmala Biotech Holdings's COGS to Revenue for the fiscal year that ended in Aug. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.148	/	1.035
	=	0.14

Pharmala Biotech Holdings's COGS to Revenue for the quarter that ended in Feb. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.01	/	0.146
	=	0.07

Pharmala Biotech Holdings (XCNQ:MDMA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Pharmala Biotech Holdings's Gross Margin % for the three months ended in Feb. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.01 / 0.146
	=	93.15 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Pharmala Biotech Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

MDXXF:USA

Address

1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.

Executives

Fraser Macdonald	Director
Perry Tsergas	Director
Shane H.d. Morris	Director, Senior Officer
Nicholas Kadysh	Director, Senior Officer

Pharmala Biotech Holdings Headlines

No Headlines